CP-751: Phase III started

Pfizer began the open-label Phase III ADVIGO 1018 trial to evaluate 150 mg Tarceva erlotinib with or without 20 mg/kg CP-751,871 in 600 patients. Tarceva is marketed by Genentech Inc. (NYSE:DNA, Sou...